Azenta (AZTA) Stock Soars 21% on Blowout Earnings: Too Late to Buy?

Azenta (AZTA) stock skyrocketed nearly 21% on Wednesday after the healthcare tech company reported fiscal fourth-quarter 2026 results that blew past analyst expectations. The company, which specializes in automated sample storage for the healthcare industry, saw its revenue rise 5% year over year to $167 million, driven by a 9% increase in its key sample management solutions unit to $94 million. Its multiomics business was flat at $73 million.

On the bottom line, adjusted net income came in at $12.3 million, or $0.28 per share, up from $9.6 million in the same period last year. This crushed the analyst consensus of just $0.12 per share, while revenue also beat expectations of barely over $160 million.

Looking ahead, Azenta provided guidance for the current quarter and the full fiscal year 2027. For the year, it expects revenue of $648 million to $660 million and adjusted EBITDA margin expansion of 200 to 250 basis points over the 2026 result. The company did not provide a bottom-line forecast.

The market's reaction was emphatic, with the stock gaining almost 21% in a single session, making it an outlier even in a strong trading day for the broader market, as the S&P 500 rose 1.3%. The surge reflects investor enthusiasm for the company's better-than-expected performance and optimistic outlook.

Azenta's strong quarterly performance and guidance are significant because they demonstrate the company's ability to execute in a challenging environment and capitalize on its large addressable market. The sample management solutions segment, which grew 9%, is the key driver, and the company's focus on automated sample storage provides cost and time savings for clients, making its services sticky and recurring.

The margin expansion guidance of 200-250 basis points is particularly important. It suggests that Azenta is not just growing revenue but also improving profitability, which could lead to higher earnings and a re-rating of the stock. The company's clean balance sheet also provides flexibility for future investments or acquisitions.

However, the multiomics segment was flat, which could be a concern if it doesn't pick up. Investors will want to see growth in both segments to sustain the momentum. Additionally, the stock's massive one-day gain may have priced in much of the good news, so future gains will depend on continued execution.

The broader healthcare tech sector has been volatile, but Azenta's unique focus on sample storage differentiates it from peers. If the company can maintain its growth trajectory and expand margins, the stock could continue to outperform.